The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
SYNIMMUNE GmbH
Tübingen, Germany
A
1-10 Employees
-
Key takeaway
SYNIMMUNE GmbH is focused on developing innovative bispecific anti-tumor antibodies, particularly for treating orphan hematopoietic malignancies.
Reference
Product
SYNIMMUNE GmbH: Bispecific antibodies
Velabs Therapeutics
Heidelberg, Germany
A
11-50 Employees
2017
Key takeaway
VERAXA Biotech specializes in the development of bispecific antibody constructs, integrating advanced solutions for targeted antibody discovery and bioconjugation. Their expertise is backed by a team with extensive experience in life sciences and technology.
Reference
Product
Bispecific Antibody Constructs | VERAXA
NanoTag Biotechnologies
Germany
A
1-10 Employees
2015
Key takeaway
NanoTag Biotechnologies is focused on developing affinity solutions based on single-domain antibodies (sdAbs) for the life sciences and biomedical fields. They emphasize their expertise in creating high-quality, validated bi-specific sdAb fusions, which are relevant to advancements in therapeutic and diagnostic applications.
Reference
Product
Bi-specific sdAb fusions - NanoTag Biotechnologies
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
IcanoMAB
Polling, Germany
A
- Employees
-
Key takeaway
IcanoMAB is focused on developing precision canonical antibodies for treating various diseases, including Covid-19. They are leveraging rabbit monoclonal antibody diversity to create effective therapeutic candidates that are currently in the IND-enabling stage.
Reference
Core business
Home - IcanoMAB
Antibody Diversity and Precision Signaling matters We are developing canonical signaling monoclonal antibodies to significantly improve therapeutic treatments in Oncology, Immune-modulation, Immunology and most urgently for Covid-19 Get in Touch Our Goal We are addressing the urgent need for particular effective treatments for Covid-19 and its potentially fatal outcome driven by Acute Respiratory Distress Syndrome … Home Weiterlesen »
immunoGlobe GmbH
Planegg, Germany
A
- Employees
-
Key takeaway
The company, immunoGlobe GmbH, is dedicated to providing the scientific community with high-quality research antibodies and reagents, which may include specialized custom antibody services that could be relevant to the development of bispecific antibodies.
Reference
Core business
Home - immunoGlobe GmbH - Your Antibody Manufacturer & Service Provider
new/era/mabs GmbH
Potsdam, Germany
A
1-10 Employees
2014
Key takeaway
The company specializes in the rapid discovery and production of various types of antibodies, including innovative recombinant camelid heavy-chain antibodies, which are smaller and more stable than conventional antibodies. This capability may be particularly relevant for developing bispecific antibodies, especially for applications where traditional antibodies are not suitable due to size constraints.
Reference
Service
selma + camelid recombinant antibodies
For some applications conventional antibodies might not be suitable due to their size or the size of the requested antigen. Therefore, we offer the generation of recombinant camelid heavy-chain only antibodies. Those antibodies - highly stable and small in size - reveal a complete new spectrum of antigen-binding in the
Abcalis GmbH
Brunswick, Germany
A
1-10 Employees
2019
Key takeaway
Abcalis offers a range of antibodies, including the ability to create bispecific antibodies by fusing antigen-binding ends to various protein domains. Their recombinant technology ensures that every Abcalis® antibody can be acquired in multiple formats, supporting innovative therapeutic developments.
Reference
Core business
Abcalis – Hightech antibodies, animal free.
imusyn GmbH & Co. KG
Hanover, Germany
A
11-50 Employees
2001
Key takeaway
Imusyn is a biotechnology company that specializes in developing and producing diagnostic tests, particularly in the field of transfusion medicine and organ transplantation. They have experience in advancing allogeneic cellular therapies and have produced over 30 products, including diagnostic assays that may relate to the development and confirmation of monoclonal antibodies.
Reference
Product
Monoclonal Antibodies - imusyn GmbH & Co. KG
Yumab
Brunswick, Germany
A
11-50 Employees
2012
Key takeaway
YUMAB is a biotechnology company specializing in the development of fully human therapeutic antibodies, leveraging over 30 years of expertise in recombinant antibody technologies. Their innovative platform and commitment to nature-derived human antibody sequences minimize toxicity and immunogenicity, enhancing the drug development process.
Reference
Core business
Home - YUMAB GmbH
YUMAB is a world leading provider of contract research, technologies, and R&D services for the development of fully human, therapeutic antibodies.
Biogenes
Berlin, Germany
A
101-250 Employees
1992
Key takeaway
BioGenes specializes in customized antibody development and immunoassays, making it a key player in the pharma and biotech industry. With a focus on quality and a dedicated team, they offer services that could be relevant for those interested in bispecific antibodies.
Reference
Core business
Custom Antibody Services | BioGenes GmbH
Technologies which have been searched by others and may be interesting for you:
The Bispecific Antibody industry in Germany presents several key considerations for interested parties. Regulatory frameworks are stringent, with the European Medicines Agency overseeing the approval processes, emphasizing safety and efficacy. Understanding the complexities of clinical trials is crucial, as these can be lengthy and resource-intensive. The competitive landscape features both established pharmaceutical giants and innovative biotech startups, creating a dynamic environment for collaboration and competition. Opportunities exist due to Germany's strong research infrastructure and funding initiatives supporting biopharmaceutical innovations. Additionally, advancements in personalized medicine and immunotherapy are driving market relevance, positioning bispecific antibodies as significant players in treating complex diseases like cancer. Environmental concerns are increasingly pertinent, especially regarding sustainable manufacturing practices and waste management in biopharmaceutical processes. Companies must also navigate challenges such as high development costs, patent issues, and market entry barriers. Keeping abreast of global trends and technological advancements will be vital for companies aiming to thrive in this evolving sector. Overall, a comprehensive understanding of these factors will empower stakeholders in making informed decisions within the Bispecific Antibody industry in Germany.
Some interesting numbers and facts about your company results for Bispecific Antibody
| Country with most fitting companies | Germany |
| Amount of fitting manufacturers | 1258 |
| Amount of suitable service providers | 1387 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 1992 |
| Youngest suiting company | 2019 |
Some interesting questions that has been asked about the results you have just received for Bispecific Antibody
What are related technologies to Bispecific Antibody?
Based on our calculations related technologies to Bispecific Antibody are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Which industries are mostly working on Bispecific Antibody?
The most represented industries which are working in Bispecific Antibody are Other, Biotechnology, IT, Software and Services, Medical, Pharmaceuticals
How does ensun find these Bispecific Antibody Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.
